Jeremiah Heredia

Jeremiah Heredia is a scientist at Codexis, Inc. since January 2020, where expertise includes designing in vitro characterization studies for AAV gene therapy targeting hemophilia A and successfully bioengineering FVIII protein for enhanced performance in human cells. Prior experience as a graduate researcher at the University of Illinois at Urbana-Champaign involved innovative deep mutational scanning methods and the discovery of CXCR4 mutations that improved ligand binding. Jeremiah's earlier roles included the production of mixed micelles during a scholarship at California State University-Los Angeles and the introduction of new laboratory methods at San Jose State University, alongside summer research at the University of California San Diego focusing on chemokine receptor manipulation. Jeremiah holds a Ph.D. in Biochemistry from the University of Illinois Urbana-Champaign, a Master's degree from California State University, Los Angeles, and a Bachelor's degree from San Jose State University.